5.14
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They ar…
Indirect-acting cholinergic agonists act by inhibiting acetylcholinesterases, to prevent ACh hydrolysis and enhance cholinergic activity in the body.
The pharmacokinetic properties of these agents are influenced by their structural characteristics.
For instance, agents bearing a quaternary nitrogen are relatively polar, resulting in poor oral absorption. So, the effective oral doses required are higher than the equivalent parenteral dose. Additionally, their low-lipid solubility restricts CNS distribution.
In contrast, agents with tertiary substitution being less polar are well absorbed by different routes, including the ocular route. So, they are commonly used as topical eye drops.
Organophosphates, on the other hand, are highly lipid-soluble and are rapidly absorbed by all routes. They are readily distributed throughout the body, including the CNS.
Following the distribution, these agents are metabolized by esterases in the liver, plasma and skeletal muscles.
The resulting metabolites formed are primarily excreted unchanged through the renal route.
View the full transcript and gain access to JoVE Core videos
Q1: How do indirect-acting cholinergic agonists enhance cholinergic activity?
Indirect-acting cholinergic agonists inhibit acetylcholinesterase enzymes, preventing the breakdown of acetylcholine (ACh) in the body. By blocking ACh hydrolysis, these agents allow acetylcholine to accumulate at cholinergic synapses, thereby enhancing cholinergic neurotransmission. This mechanism differs from direct agonists, which bind receptors directly.
Q2: Why do quaternary nitrogen agents have poor oral absorption?
Agents with quaternary nitrogen are highly polar molecules, which limits their ability to cross cell membranes and be absorbed through the gastrointestinal tract. This poor oral bioavailability requires higher effective oral doses compared to equivalent parenteral doses. Their polarity also restricts distribution to the central nervous system.
Q3: What are the advantages of tertiary amine indirect-acting cholinergic agonists?
Tertiary amine agents like physostigmine are less polar than quaternary compounds, allowing excellent oral absorption and penetration across the blood-brain barrier and eye tissues. This property makes them ideal for topical ophthalmic use as eye drops and enables systemic distribution throughout the body.
Q4: How do organophosphates differ in their pharmacokinetic properties?
Organophosphates are highly lipid-soluble compounds that are rapidly absorbed through all routes, including mucous membranes, skin, and lungs. They readily distribute throughout the body and cross the blood-brain barrier, making them particularly dangerous. They are metabolized by esterases in the liver, plasma, and skeletal muscles.
Q5: What determines the duration of action for reversible anticholinesterases?
Duration depends on the agent's chemical structure and stability. Short-acting agents like edrophonium contain simple alcohol groups and are rapidly eliminated renally, lasting ten to twenty minutes. Intermediate-acting agents like neostigmine contain carbamate groups that are slowly hydrolyzed, producing effects lasting twenty minutes to six hours.
Q6: How are indirect-acting cholinergic agonists metabolized and eliminated?
These agents are metabolized by cholinesterase enzymes located in the liver, plasma, and skeletal muscles. The resulting metabolites are primarily excreted unchanged through the kidneys via renal elimination. Organophosphates can gradually age to become resistant to hydrolysis, leading to prolonged effects and potential toxicity.
Q7: Why is lipid solubility important for indirect-acting cholinergic agonist distribution?
Lipid solubility determines an agent's ability to cross biological membranes and penetrate tissues. Highly lipid-soluble agents like organophosphates readily distribute throughout the body and cross the blood-brain barrier, causing systemic and central nervous system effects. Low lipid solubility restricts distribution, limiting side effects.